1019 related articles for article (PubMed ID: 18446337)
1. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
Diaz-Montero CM; Salem ML; Nishimura MI; Garrett-Mayer E; Cole DJ; Montero AJ
Cancer Immunol Immunother; 2009 Jan; 58(1):49-59. PubMed ID: 18446337
[TBL] [Abstract][Full Text] [Related]
2. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.
Wesolowski R; Duggan MC; Stiff A; Markowitz J; Trikha P; Levine KM; Schoenfield L; Abdel-Rasoul M; Layman R; Ramaswamy B; Macrae ER; Lustberg MB; Reinbolt RE; Mrozek E; Byrd JC; Caligiuri MA; Mace TA; Carson WE
Cancer Immunol Immunother; 2017 Nov; 66(11):1437-1447. PubMed ID: 28688082
[TBL] [Abstract][Full Text] [Related]
3. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
4. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
5. [Myeloid-derived suppressor cells in patients with breast cancer].
Gonda K; Shibata M; Ohtake T; Yasuda M; Abe N; Watanabe K; Ando J; Okano M; Onozawa H; Tachibana K; Ohto H; Takenoshita S
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1363-8. PubMed ID: 22996770
[TBL] [Abstract][Full Text] [Related]
6. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.
Angell TE; Lechner MG; Smith AM; Martin SE; Groshen SG; Maceri DR; Singer PA; Epstein AL
Thyroid; 2016 Mar; 26(3):381-9. PubMed ID: 26756227
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
Alizadeh D; Trad M; Hanke NT; Larmonier CB; Janikashvili N; Bonnotte B; Katsanis E; Larmonier N
Cancer Res; 2014 Jan; 74(1):104-18. PubMed ID: 24197130
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
[TBL] [Abstract][Full Text] [Related]
11. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
[TBL] [Abstract][Full Text] [Related]
12. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
[TBL] [Abstract][Full Text] [Related]
14. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
15. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
17. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.
Markowitz J; Brooks TR; Duggan MC; Paul BK; Pan X; Wei L; Abrams Z; Luedke E; Lesinski GB; Mundy-Bosse B; Bekaii-Saab T; Carson WE
Cancer Immunol Immunother; 2015 Feb; 64(2):149-59. PubMed ID: 25305035
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
Wang J; McGuire TR; Britton HC; Schwarz JK; Loberiza FR; Meza JL; Talmadge JE
Clin Exp Metastasis; 2015 Feb; 32(2):111-24. PubMed ID: 25617965
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
[TBL] [Abstract][Full Text] [Related]
20. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
